miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy


To cite this version:
Ruth Rodriguez-Barrueco, Erin A Nekritz, François Bertucci, Jiyang Yu, Felix Sanchez-Garcia, et al.. miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes and Development, 2017, 31 (6), pp.553-566. 10.1101/gad.292318.116. hal-01787959

HAL Id: hal-01787959
https://hal.science/hal-01787959
Submitted on 7 May 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy

Ruth Rodriguez-Barrueco,1,2,7 Erin A. Nekritz,1,7 François Bertucci,3 Jiyang Yu,4 Felix Sanchez-Garcia,5 Tizita Z. Zeleke,1 Andrej Gorbatenko,1 Daniel Birnbaum,3 Elena Ezhkova,6 Carlos Cordon-Cardo,1 Pascal Finetti,3 David Llobet-Navas,1,2 and Jose M. Silva1

1Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA; 2Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne NE1 3BZ, United Kingdom; 3Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Aix-Marseille Université, Marseille 13009, France; 4St. Jude Children’s Research Hospital, Kay Research and Care Center, I6053, Memphis, Tennessee 38105, USA; 5Department of Systems Biology, Center for Computational Biology and Bioinformatics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York 10032, USA; 6Department of Cell, Developmental, and Regenerative Biology, Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA

The female mammary gland is a very dynamic organ that undergoes continuous tissue remodeling during adulthood. Although it is well established that the number of menstrual cycles and pregnancy (in this case transiently) increase the risk of breast cancer, the reasons are unclear. Growing clinical and experimental evidence indicates that improper involution plays a role in the development of this malignancy. Recently, we described the miR-424(322)/503 cluster as an important regulator of mammary epithelial involution after pregnancy. Here, through the analysis of ~3000 primary tumors, we show that miR-424(322)/503 is commonly lost in a subset of aggressive breast cancers and describe the genetic aberrations that inactivate its expression. Furthermore, through the use of a knockout mouse model, we demonstrate for the first time that loss of miR-424(322)/503 promotes breast tumorigenesis in vivo. Remarkably, we found that loss of miR-424(322)/503 promotes chemoresistance due to the up-regulation of two of its targets: BCL-2 and insulin-like growth factor-1 receptor (IGF1R). Importantly, targeted therapies blocking the aberrant activity of these targets restore sensitivity to chemotherapy. Overall, our studies reveal miR-424(322)/503 as a tumor suppressor in breast cancer and provide a link between mammary epithelial involution, tumorigenesis, and the phenomenon of chemoresistance.

[Keywords: chemoresistance; breast cancer; microRNA; tumor suppressor]

Supplemental material is available for this article.

Received October 18, 2016; revised version accepted March 6, 2017.
on Hormonal Factors in Breast Cancer 2012) and pregnancy (in this case, transiently) [Lambe et al. 1994] increase the risk of breast cancer, the reasons are unclear. Growing clinical and experimental evidence indicates that improper involution plays a role in the development of this malignancy [Watson 2006; Radisky and Hartmann 2009]. Not surprisingly, some of the pathways described to have a role in this process are also involved in tumorigenesis. Two main discrete phases of involution have been described. The first phase is initiated by milk stasis and the release of soluble factors such as TGF-β [Nguyen and Pollard 2000; Bierie et al. 2009] and IL-6 cytokine family members LIF [Kritikou et al. 2003] and OSM [Tiffany et al. 2008]. These activate STAT3 [Chapman et al. 1999; Kreuzaler et al. 2011; Sargeant et al. 2014], NF-κB [Baxter et al. 2006], and insulin-like growth factor (IGF) signaling, [Neuenschwander et al. 1996; Allan et al. 2004], leading to apoptotic [Jager et al. 1997; Walton et al. 2001; Rucker et al. 2011] and nonapoptotic [Kreuzaler et al. 2011] programmed cell death. During the second phase, nonepithelial cells are also critical, and macrophage function [Hutchins et al. 2012; O’Brien et al. 2012] and high protease activity from the stroma [matrix metalloproteinases] [Talhouk et al. 1992; Fata et al. 2001; Green and Lund 2005] are required. Despite the above, overall, our understanding of the molecular mechanisms involved in mammary epithelial dynamics is far from complete. Moreover, how deregulation of specific genes during involution influences tumorigenesis is poorly understood.

Recently, through the generation of a knockout mouse model, we discovered that the microRNA (miRNA) cluster miR-424(322)/503 is a TGF-β-induced regulator of involution in the mammary epithelium [Llobet-Navas et al. 2014a,b]. Importantly, the miR-424(322)/503 locus is commonly lost in a subset of breast cancers that have clinicopathological characteristics of poor prognosis. This miRNA cluster contains two miRNAs, miR-424(322) and miR-503, which belong to the miR-16 family and consequently can modulate the expression of the same target genes [Liu et al. 2008; Finnerty et al. 2010]. Our studies demonstrated that part of the biological activity of miR-424(322)/503 in the mammary epithelium is mediated by its ability to down-regulate the expression of CDC25A, BCL-2, and IGF-1 receptor (IGF1R). Notably, these three genes have been found to be overexpressed in human breast cancers presenting oncogenic functions [CDC25A [Cangi et al. 2000], IGF1R [Kucab and Dunn 2003], and BCL-2 [Dawson et al. 2010]]. Furthermore, up-regulation of BCL-2 [Dawson et al. 2010; Colitti 2012; Vaillant et al. 2013] and IGF1R signaling (Kucab and Dunn 2003; Hendrickson and Haluska 2009; Vu and Claret 2012) is a common and well-established mechanism that cancer cells, including breast cancers, use to overcome apoptosis induced by chemotherapy. Thus, based on the above findings, we aimed to investigate a putative tumor suppressor function for the miR-424(322)/503 cluster and specifically the impact that loss of this miRNA cluster has on response to chemotherapy.

Results

The miR-424(322)/503 cluster is lost in breast cancers

Our previous studies revealed that miR-424[322]/503−/− female mice present defects in mammary gland involution and display alveolar hyperplasia after pregnancy [Llobet-Navas et al. 2014a]. Thus, we decided to investigate a putative tumor suppressor role for this miRNA cluster in breast cancer. First, we pooled the METABRIC [Molecular Taxonomy of Breast Cancer International Consortium] [Curtis et al. 2012] and the BRCA-The Cancer Genome Atlas [TCGA] [The Cancer Genome Atlas Network 2012] data sets, which are the two largest data sets containing matched DNA copy number alteration [CNA] and expression analysis [coding genes and miRNAs] of primary breast cancers. We then analyzed the 2165 pretherapeutic samples from patients with nonmetastatic primary invasive breast cancer who underwent surgery and had available follow-up data [Supplemental Table S1]. In each data set, the miR-424(322)/503 locus was deleted in ~14% of breast cancers, and its deletion correlated with lower expression levels of the mature miR-424 and miR-503 forms [Fig. 1A]. Although small deletions (<2 Mb) occurred, the majority was chromosomal arm losses resulting in heterozygosis [Ht] [Fig. 1A].

We then searched for correlations between miR-424(322)/503 status [302 cases with and 1863 cases without deletion, referred to here as miR-DEL and miR-non-DEL, respectively] and the clinicopathological and molecular characteristics of the tumors. Loss of miR-424(322)/503 was associated with poor prognosis characteristics such as high-grade [histological and genomic-grade index [GGI]] [Sotiriou et al. 2006] larger pathological tumor size, triple-negative [TN] status, strong cell proliferation [KI67 mRNA expression], and GGI signature [Fig. 1B; Supplemental Table S2]. Commonly, primary breast cancers are also stratified into different molecular subtypes based on genome-wide studies of mRNA expression and CNAs [Perou et al. 2000; Curtis et al. 2012]. We found that deletion of this miR cluster was more frequent in tumor subtypes with aggressive behavior such as basal and luminal B [Fig. 1C] and the integrative clusters 1, 2, 6, 9, and 10 [Supplemental Fig. S1A].

Based on its association with poor prognosis characteristics, we hypothesized that loss of the miR-424(322)/503 cluster could influence patient survival. The median follow-up was 63 mo (range 1–302), during which 1711 patients remained alive, and 454 patients died. The 5-yr overall survival was 84% [95% CI 82–86]. The “miR-DEL” subgroup was associated with shorter overall survival in the whole population, with 75% 5-yr overall survival [95% CI 70–81] versus 85% [95% CI 83–87] for the “miR-non-DEL” subgroup [P = 3.60 × 10−4, log-rank test] [Fig. 1D; Supplemental Table S3]. A similar result was observed in basal tumors, in which the 5-yr overall survival was 85% [95% CI 43–69] in the case of miR deletion and 76% [95% CI 71–82] in the absence of deletion [P = 4.01 × 10−3, log-rank test] [Fig. 1D; Supplemental Fig. S1B; Supplemental Table S3]. No prognostic value was observed in the other molecular subtypes [Supplemental Fig.
miR-424/503 is a breast cancer tumor suppressor

Figure 1. miR-424(322)/503 is lost in breast cancer and is associated with poor prognosis and aggressive subtypes. [A] Copy number profile of the X chromosome in human breast cancers [METABRIC plus TCGA data sets], highlighting the chromosomal region containing the miR-424(322)/503 locus. The correlation between copy number and expression for surrounding genes is included at the bottom. The bar graph and box plots show the number of breast cancers presenting deletion (DEL) of the miR-424(322)/503 locus as well as the association between copy number and expression for miR-424(322) and miR-503. The bar graphs show the association between deletion of the miR-424(322)/503 locus with grade [B] and PAM50 molecular subtypes [C]. [D] Overall survival of breast cancer patients with and without deletion of the miR-424(322)/503 locus [all patients and basal tumors are shown]. [E] The miR-424(322)/503 cluster is monoallelically expressed as shown by sequencing a single-nucleotide polymorphism [SNP] located between the miRNAs in the cluster at the DNA and RNA level. Chromatin immunoprecipitation (ChIP) assays confirm that the expressed allele is associated with the active transcription elongation histone mark H3K36me3. [F] Methylation status analysis of the miR-424(322)/503 locus in breast cancers [TCGA-BRCA data set] with and without deletion of the locus. Each dot represents an individual primary tumor.
In multivariate analysis, the "miR-DEL" status retained unfavorable prognostic significance in the whole population ($P = 2.95 \times 10^{-2}$, Wald test, hazard ratio [HR] = 1.34 [95% CI 1.03–1.75]) and the basal subtype ($P = 1.4 \times 10^{-2}$, Wald test, HR = 1.99 [95% CI 1.30–3.04]) (Supplemental Table S3).

We previously described the generation of a C57BL/6/miR-424(322)/503−/− female mice model with wild-type FVB mice for more than six generations to produce a >98.5% clean FVB/miR-424(322)/503−/− background (Supplemental Fig. S2A). All experiments in this study were done in the FVB background, and we refer to them here as the miR-424(322)/503−/− model. Next, the mammary epithelia of >1-yr-old FVB wild-type, miR-424(322)/503−/−, and miR-424(322)/503−/− virgin females were evaluated by carmine red staining (Fig. 2A) and H&E staining (Fig. 2B). Remarkably, while none of the wild-type animals presented mammary epithelial abnormalities, all of the miR-424(322)/503−/− females displayed enlargement of the terminal ductal lobular units, and we were able to detect microscopic invasive carcinomas in 50% of them (Fig. 2E). Heterozygous miR-424(322)/503+−/− animals presented an intermediate phenotype where hyperplasia predominated (Fig. 2E). Ki-67 immunohistochemistry (IHC) revealed that these lesions presented a higher proliferative index than the mammary epithelia of wild-type animals (Fig. 2B,E).

Because the miR-424(322)/503 cluster has a known role in post-lactational mammary involution (Llovet-Navas et al. 2014a) and we showed previously that pregnancy promotes accumulation of abnormalities in the mammary epithelium of knockout animals, we next investigated the development of breast carcinomas in parous miR-424(322)/503−/− females. Carmine red staining (Fig. 2C) and H&E staining (Fig. 2D) of mammary glands from >1-yr-old parous mice that passed through one round of pregnancy between the ages of 4 and 7 mo showed a very enlarged mammary epithelium in miR-424(322)/503−/− animals, with a large majority of the animals (73%) presenting microscopic invasive carcinomas (Fig. 2E). Although the majority of the invasive lesions was microscopic, palpable tumors developed in a small fraction of the animals (two out of 40). Overall, these data demonstrate that loss of miR-424(322)/503 induces mammary epithelial tumorigenesis that is promoted by pregnancy (Supplemental Fig. S2B).

Only the expressed allele was found to be associated with this histone mark (Fig. 1F). Overall, the above confirmed that, in mammary epithelial cells of female origin, miR-424(322)/503 is monoallelically expressed.

Finally, we investigated which of the two miR-424 (322)/503 alleles (active or inactive) was targeted by the deletion observed in breast cancers. DNA hypermethylation is linked with the inactive X chromosome (Xi), while hypomethylation is seen at the Xa (Heard 2004; Briggs and Reijo Pera 2014), we reasoned that deletion of the active allele would increase the level of methylation detected at the miR-424(322)/503 locus by methylation arrays. Thus, we integrated the methylation profiles and the CNA data available in the TCGA-BRCA database (The Cancer Genome Atlas Network 2012). This study revealed that breast cancers with deletions in the miR-424 (322)/503 locus present a significantly higher level of methylation (Fig. 1F). This result supports the notion that the active allele is selectively deleted, whereas the methylated inactive allele remains intact.

CDC25A, BCL-2, and IGFI R oncogenes are up-regulated in miR-424(322)/503−/− deficient mammary tumors

The biological functions of miRNAs are mediated by their ability to attenuate the expression of specific mRNAs. Both miR-424(322) and miR-503 belong to the miR-16 family (Liu et al. 2008; Finnerty et al. 2010), and we showed previously (Llovet-Navas et al. 2014a,b) that they target three genes that have been found to be overexpressed, presenting oncogenic functions in human breast cancers (CDC25A [Cangi et al. 2000], IGFI R [Kucab and Dunn 2003], and BCL-2 [Dawson et al. 2010]). CDC25A is a key player in the progression of the cell cycle (Nilsson and Hoffmann 2000). IGFI R is the canonical receptor for IGFI (Pollak 2012). IGFI binding leads to the activation of two main signaling pathways: the PI3K–AKT/PKB and Ras–MAPK pathways. BCL-2 is the founding member of the BCL-2 family of apoptosis regulator proteins, and its key role in the intrinsic apoptosis pathway is well established (Colitti 2012). Thus, we investigated the status of...
these proteins in cancer cells deficient in miR-424(322)/503. To evaluate the correlation between the expression of miR-424(322)/503 and these genes in primary tumors, we analyzed the RPPA (reverse phase protein array) data available from the TCGA-BRCA database. These data provide expression levels for ∼200 proteins, including IGF1R and BCL-2, in >400 primary breast cancers with matched information regarding miR-424(322) and miR-503 expression. Remarkably, these studies showed a significant increase of both IGF1R and BCL-2 protein in breast cancers with low expression of miR-424 (Fig. 3A) and miR-503 (Supplemental Fig. S3A).

Next, we tested in a mouse model of breast cancer how loss of miR-424(322)/503 impacts the expression of these targets and influences breast tumorigenesis. As shown before, loss of the miR-424(322)/503 cluster occurs in different breast cancer subtypes, including ErbB2/HER2+ tumors (see Fig. 1C; Supplemental Fig. S1D). Thus, we crossed our miRNA cluster knockout animals with the FVB-Tg(MMTV-ErbB2)NK1Mul/J mouse model (referred to here as MMTV-Neu for simplification) in which an activated oncogene HER2 drives tumor formation in the mammary gland (Supplemental Fig. S3B; Muller et al. 1988). Female MMTV-Neu mice develop multifocal palpable mammary tumors efficiently after pregnancy (Ebbeisen et al. 2016). We generated FVB-Tg[MMTV-ErbB2]NK1Mul/J/miR-424(322)/503−/− animals [MMTV-Neu-miR_KO] and compared the expression of IGF1R, BCL-2, and CDC25A in size-matched tumors [0.5–0.8 cc] with MMTV-Neu animals. Here we found that the expression of all three miR-424(322)/503 targets was strongly up-regulated in mammary tumors from MMTV-Neu-miR_KO animals (Fig. 3B). As expected, the higher expression of IGF1R led to elevated levels of phospho-IGF1R and phospho-AKT (Fig. 3B). Additionally, the growth of MMTV-Neu-miR_KO tumors was accelerated (Fig. 3C), and intratumoral Ki-67 immunostaining revealed a significantly higher proliferation index (Fig. 3D), as observed in clinical samples. Despite the aforementioned differences, both animal models developed adenocarcinomas that were histologically identical.

Loss of miR-424(322)/503 induces resistance to anti-cancer therapy due to up-regulation of BCL-2 and IGF1R

Up-regulation of BCL-2 (Dawson et al. 2010; Colitti 2012) and IGF1R signaling (Kucab and Dunn 2003; Hendrickson and Haluska 2009) is a common and well-established mechanism that cancer cells, including breast cancers, use to overcome apoptosis induced by chemotherapy. As the miR-424(322)/503 cluster targets both pathways and as loss of miR-424(322)/503 in breast cancer patients is associated with higher protein levels of IGF1R and BCL-2...
we anticipated that loss of miR-424(322)/503 may induce resistance to chemotherapeutic drugs. Because of the clinical relevance of treatment resistance, we decided to investigate the role of miR-424(322)/503 in this phenomenon. Thus, we compared the response to the standard chemotherapeutic drug paclitaxel between mammary tumors in MMTV-Neu and MMTV-Neu-miR_KO animals (Fig. 4A). Female mice underwent one round of pregnancy, and we subsequently followed the growth of mammary carcinomas. Once the mammary tumor mass reached \( \sim 500 \text{ mm}^3 \), these animals were treated twice per week with an intraperitoneal dose of 6 mg/kg paclitaxel (Domingo-Domenech et al. 2012; Hannesdottir et al. 2013; Usary et al. 2013), and the response to this anticancer treatment was monitored (Fig. 4B). This study showed that while MMTV-Neu tumors responded well to paclitaxel, showing significant shrinkage in just 2 wk, MMTV-Neu-miR_KO tumors were refractory to this treatment and continued growing almost at the rate of the untreated tumors (Fig. 4B; Supplemental Fig. S4A). Additionally, evaluation of apoptosis by cleaved Caspase-3 immunostaining in treated samples revealed that MMTV-Neu-miR_KO tumors presented a significant reduction in the level of apoptosis compared with MMTV-Neu tumors (Fig. 4C).

Next, we reasoned that if high levels of BCL-2 and IGF1R indeed mediate resistance to chemotherapy in miR-424(322)/503-deficient breast cancers, then blocking their activity may restore sensitivity to treatment. Importantly, small molecule inhibitors that block the BCL-2 and IGF1R oncogenic pathways already exist in clinical trials. BH3 mimetics that block the anti-apoptotic activity of BCL-2 proteins have been developed and show considerable promise (Oltersdorf et al. 2005; Witham et al. 2007; Roberts et al. 2012; Vaillant et al. 2013). In patients, treatment with early-generation inhibitors induced dose-dependent thrombocytopenia due to unintended targeting of BCL-XL, leading to loss of mature platelets [Mason et al.
However, new-generation inhibitors such as ABT-199/venetoclax have greater specificity for BCL-2, thus preventing this issue (Witham et al. 2007; Vaillant et al. 2013). ABT-199/venetoclax is currently under investigation in multiple phase 2 and phase 3 clinical trials, mainly for blood-related malignancies, and has been approved recently by the FDA for treatment of chronic lymphocytic leukemia [https://clinicaltrials.gov/ct2/results?term=ABT-199+&Search=Search]. Multiple IGF1R inhibitors, humanized monoclonal antibodies (mAbs), and small molecule tyrosine kinase inhibitors (TKIs) have been evaluated in clinical trials (Chen and Sharon 2013; King et al. 2014). Although their efficacy in unselected patients has been limited, these targeted approaches can induce strong anti-tumor activities in selected tumors, including tumors refractory to standard therapies (Chen and Sharon 2013; King et al. 2014). Notably, multiple data from experimental models support the use of these inhibitors in cancer cells with elevated IGF1R expression and activated IGF-1 signaling (King et al. 2014). Among the inhibitors, BMS-754807 is one of the most specific TKIs for which multiple clinical trials have been conducted.

**Figure 4.** Loss of miR-424/503 induces resistance to anti-cancer therapy due to up-regulation of BCL-2 and IGF1R. (A) Mammary tumor volumes emerging in MMTV-Neu and MMTV-Neu-miR_KO animals were monitored until they reached ~500 mm³, and then animals were treated twice per week with paclitaxel (PTX). (B) Growth curves showing the response to paclitaxel treatment. (C) Cleaved Caspase-3 immunostaining in tumors from MMTV-Neu and MMTV-Neu-miR_KO models after treatment with paclitaxel. (D) Illustration of the strategy to evaluate the use of ABT-199 and BMS-754807 to reverse chemoresistance in MMTV-Neu-miR_KO animals. (E) Growth curves showing the response to paclitaxel alone versus paclitaxel plus BMS-754807 and ABT-199. (F) Cleaved Caspase-3 immunostaining in the MMTV-Neu-miR_KO tumors from E. For animal studies, five to eight animals were used per cohort.
have been completed, demonstrating safety and tolerability (https://clinicaltrials.gov/ct2/results?term=BMS-754807&Search=Search).

Previously, we showed that miR-424(322)/503−/− mouse mammary epithelial cells (MMECs) are more resistant to chemotherapeutic agents such as paclitaxel than wild-type counterparts (see also Supplemental Fig. S4B; Llobet-Navas et al. 2014a). Thus, we first tested whether treating these cells with the above-mentioned inhibitors would resensitize them. Interestingly, treating these cells with each individual inhibitor increased their sensitivity to paclitaxel, and this effect was increased when they were combined [Supplemental Fig. S4C]. Based on these data, we next compared the response of MMTV-Neu-miR_KO mice treated with paclitaxel alone (as described above) versus animals treated with paclitaxel plus ABT-199 and BMS-754807 administered by gavage at 50 mg/kg three times per week [Fig. 4D; Supplemental Fig. S4D; Hou et al. 2011; Vaillant et al. 2013]. Remarkably, blocking IGF1R activation and BCL-2 through the use of these inhibitors resensitized MMTV-Neu-miR_KO tumors to paclitaxel [Fig. 4E; Supplemental Fig. S4E], and the tumors showed a significant increase in treatment-induced apoptosis [Fig. 4F]. No significant differences in the response to paclitaxel were observed when parental MMTV-Neu tumors were treated with these inhibitors (Supplemental Fig. S4F).

Based on the results from our animal models shown above, we postulated that the unfavorable prognosis of loss of the miR-424(322)/503 locus could be mediated at least in part by the poor response of miR-424(322)/503-deficient cells to treatment. Thus, we analyzed the prognostic value of miR-424(322)/503 loss in our data set according to the delivery or lack of adjuvant chemotherapy; that is, we searched for an association between miR-424(322)/503 status and the benefit of chemotherapy in terms of overall survival. In univariate analysis, an interaction was observed in the whole population (P = 0.02): In the chemotherapy-naïve subgroup, patients with “miR-DEL” and patients with “miR-non-DEL” tumors exhibited similar overall survival (P = 0.16, Wald test), whereas, in the chemotherapy-treated subgroup, patients with “miR-DEL” tumors exhibited shorter overall survival than patients with “miR-non-DEL” tumors (P = 1.61 × 10−4, Wald test) [Fig. 5A; Table 1]. Therefore, exposure to chemotherapy was associated with a lesser risk of death and consequently a stronger benefit in patients with “miR-non-DEL” tumors [HR = 1.67 [95% CI 1.32–2.12], P = 2.06 × 10−5] than in patients with “miR-DEL” tumors [HR = 2.74 [95% CI 1.76–4.27]]. Analysis per molecular subtype revealed a similar trend in the basal subtype (P = 0.09) [Fig. 5B; Table 1], while lesser or no effect was observed in other molecular subtypes [Supplemental Table S4]. Importantly, in multivariate analysis [Table 1], the interaction remained significant in the whole population (P = 1.58 × 10−3) and tended toward significance in the basal subtype (P = 0.10). Thus, these data confirm that, in breast cancer, the status of the miR-424(322)/503 cluster is associated with reduced response to chemotherapy, particularly in the basal subtype.

Discussion

Transformation of normal cells is driven by the aberrant function of genes that positively (oncogenes) and negatively (tumor suppressors) regulate the cancer phenotype [Hanahan and Weinberg 2011]. Identification and characterization of those genes that provide cells with the capabilities necessary for tumor initiation and progression are critical to understanding tumorigenesis. The identification of tumor suppressors has been historically challenging due to their recessive nature and the diverse mechanisms by which they are inactivated. Here we report the tumor suppressor function of the miR-424(322)/503 cluster in breast cancers.

The miR-424(322)/503 cluster expresses miR-424(322) and miR-503, two miRNAs that belong to the miR-16 family. In humans, this family consists of at least 10 members that have been shown to regulate an array of processes such as cell division, metabolism, stress response, and angiogenesis [Finnerty et al. 2010]. Two of its members, miR-15a and miR-16-1, have been associated previously with tumor suppressor functions mainly in blood cancers [Aqeilan et al. 2010; Finnerty et al. 2010]. Although a role for miR-424 and miR-503 in tumorigenesis has been
Table 1. Univariate and multivariate interaction analysis between miR-424(322)/503 status and chemotherapy for overall survival in the whole population and in the basal subtype

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>All</th>
<th>Basal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Univariate</td>
<td>Multivariatea</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>HR [95 CI]</td>
</tr>
<tr>
<td>Chemotherapy, yes vs. no_miR-non-DEL</td>
<td>1863</td>
<td>1.67 [1.32–2.12]</td>
</tr>
<tr>
<td>Chemotherapy, yes vs. no_miR-DEL</td>
<td>302</td>
<td>2.74 [1.76–4.27]</td>
</tr>
<tr>
<td>miR, DEL vs. non-DEL_chemotherapy no</td>
<td>1658</td>
<td>1.25 [0.92–1.70]</td>
</tr>
<tr>
<td>Interaction chemotherapy::miR424/503</td>
<td>2165</td>
<td>1.77 [1.08–2.91]</td>
</tr>
</tbody>
</table>

*Multivariate analysis included variables with P-value < 0.10 in univariate prognostic analysis.
suggested, these studies are conflicting, and both tumor-suppressing (Xu et al. 2013a; Chong et al. 2014; Li et al. 2015) and tumor-promoting (Zhang et al. 2014; Ide et al. 2015) functions have been proposed. Arguably, a key reason for this discrepancy was that previous reports were based mainly on association studies in which miRNA expression was compared between cancerous and noncancerous tissues. Additionally, functional studies were limited to the use of cell lines in which miR-424 and miR-503 were overexpressed. Here, through the use of a knockout mouse model, we demonstrate for the first time that loss of miR-424(322)/503 promotes breast tumorigenesis in vivo and describe the genetic aberrations that inactivate its expression in human breast cancers. Notably, according to our knowledge, this is the first report of a miRNA with tumor suppressor functions that is able to generate solid tumors in mice when deleted without the use of cooperating alterations (e.g., P53-null or MYC-overexpressing mouse strains).

How does loss of miR-424(322)/503 impact mammary tumorigenesis and tumor progression? Our previous studies (Llobet-Navas et al. 2014a,b) and the new data shown here have revealed that this miRNA cluster modulates the expression of at least three well-known oncogenes (CDC25A, BCL-2, and IGF1R) in human and mouse primary breast cancers. Others have also shown that, in other cell types, this cluster targets additional genes involved in cell cycle progression [Nakashima et al. 2010; Xu et al. 2013b], angiogenesis [Ghosh et al. 2010; Nakashima et al. 2010], immune response [Xu et al. 2016], cell metabolism [Long et al. 2013], and cell adhesion [Chong et al. 2014]. Thus, we propose that aberrant high levels of these targets due to loss of miR-424(322)/503 support multiple hallmarks of cancer leading to tumorigenesis [Fig. 6A].

Chemoresistance is one of the most pressing problems faced by oncologists [Raguz and Yague 2008]. Despite the general use of chemotherapy as the standard of care in the vast majority of anti-cancer regimens, life-threatening intrinsic and acquired resistance commonly emerges [Wilson et al. 2006]. In breast cancers, this is especially problematic for patients whose tumors are of the TN and basal subtypes. As these tumors do not express steroid hormone receptors or present alterations in the HER2 oncogene, they cannot benefit from targeted therapies specifically designed against these cancer determinants. Thus, chemotherapy remains the only possible therapeutic option in the adjuvant or metastatic setting for these patients [Gluz et al. 2009; Brunello et al. 2013]. The studies presented here have revealed that loss of miR-424(322)/503 occurs in ~20% of TN and basal breast cancers and is associated with shorter overall survival independent of clinicopathological variables. Importantly, we linked the influence of miR-424(322)/503 loss on patient survival with the induction of chemo-resistance due to the aberrant up-regulation of defined miR-424(322)/503 targets. Our deep understanding and characterization of the miR-424(322)/503-target axes in the normal mammary epithelium [Llobet-Navas et al. 2014a,b] as well as in breast cancers have allowed us to propose targeted therapy-based combinations to block the activity of IGF1R and BCL-2 and effectively reverse chemo-resistance [Fig. 6B]. Remarkably, inhibitors such as ABT-199 or BMS-754807 that are currently under investigation in clinical trials and show promising anti-cancer activity and low toxicity represent an exciting and realistic therapeutic opportunity for patients who present chemo-resistance due to the loss of miR-424(322)/503. To this end, we performed toxicological studies in our preclinical animal models. This analysis revealed that addition of ABT-199 and BMS-754807 to paclitaxel treatment did not change the total white blood cell count but reduced the leucocyte fraction while increasing the percentage of neutrophils and monocytes. Chemical tests also showed a comparable pattern with a few exceptions [Supplemental Table S5].

There are some questions that are still unanswered due to limitations in our study and are worth discussing. We focused our studies on the impact that aberrant up-

![Figure 6](https://example.com/figure6.png)
miR-424/503 is a breast cancer tumor suppressor

Overall, our studies reveal the following major discoveries: First, we unambiguously demonstrated the tumor suppressor function of miR-424[322]/503 in breast cancers. Second, we uncovered the impact that loss of miR-424[322]/503 has on promoting chemoresistance. Finally, our molecular understanding of the genes regulated by the miR-424[322]/503 cluster identified therapeutic strategies to restore sensitivity to chemotherapy.

Materials and methods

Cell culture

All cell lines were obtained from American Type Culture Collection and Invitrogen and grown as recommended (detailed in the Supplemental Material).

Western blotting

Samples were lysed with EZ lysis buffer (1 M Tris at pH 7, 50% glycerol, 20% SDS, 1 mM sodium orthovanadate, 1 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride). Protein concentrations were determined using the protein assay kit (Bio-Rad, 500-0006). Equal amounts of proteins were subjected to SDS-PAGE and transferred to nitrocellulose membranes (GE Healthcare, 10401197). Membranes were incubated overnight at 4°C with primary antibodies and for 1 h at room temperature with secondary HRP-conjugated antibodies. The antibodies used in this study include IGF1R, BCL-2, and CDC25A from Santa Cruz Biotechnology (sc-492, sc-713, and sc-7389, respectively); p-Akt Ser473, p-IGF1R Tyr1131, and p-IGF1R Tyr1135 from Cell Signaling (4060, 3021, and 3918, respectively); and β-Actin from US Biological (A0760-40).

Experimental animals

Animal maintenance and experiments were performed in accordance with the animal care guidelines and protocols approved by the Columbia University/Mount Sinai animal care units.

Mixed background miR-424[322]/503−/− females were retro-crossed for 10 generations with FvB/NJ males (Jackson, 001800) to ensure a homogeneous FvB/NJ background. Genotyping was performed on tail samples using the Direct PCR reagent (Viagen, 202-Y). Tails were incubated in 250 µL of Direct PCR reagent and 20 mg/mL Proteinase K (New England Biolabs, P8102) for 5 h at 55°C. Samples were then incubated for 45 min at 85°C, after which they were centrifuged at full speed for 5 min. One microliter of sample was used to perform genotyping PCR using the FastStart polymerase [Roche, 0473842001]. Thermal conditions were as follows: predenaturing for 5 min at 94°C, 35× (denaturing for 30 sec at 94°C, annealing for 30 sec at 55°C, and elongation for 30 sec at 72°C), and final elongation for 7 min at 72°C. All experiments were performed under the Institutional Animal Care and Use Committee [IACUC] guidelines.

Primers used for genotyping were as follows: pair 1 (F, AAGCAGAGCTCTGGAAAAAT; R, CAACTGAAGAGCGTACAAAC) and pair 2 (F, AGTCTCGAAAACCGGACAT; R, ATT GCTCTCGATTGAC). FvB/NJ miR-424[322]/503−/− mice were crossed with MMTV-Neu mice (NK1Mul/J, Jackson, 005038) to study the effects of miR-424[322]/503 targeted deletion in mammary breast tumor growth, latency, and response to chemotherapy.
Drug administration
Paclitaxel (obtained from Columbia University Medical Center-Presbyterian Hospital) was diluted with PBS to 6 mg/mL. ABT-199 and BMS-754807 were purchased from Selleckchem. Paclitaxel (6 mg/kg) was administered intraperitoneally twice per week for 3 wk, and the combination 50 mg/kg ABT-199 + 50 mg/kg BMS-754807 was administered by gavage three times per week for 3 wk. Animals were monitored for 3 wk, and tumor volume was measured twice per week using the ellipsoid volume formula 1/2 × L × W × H.

ChIP
A standard immunoprecipitation protocol was followed. The detailed protocol is described in the Supplemental Material.

Monoallelic expression
Genomic DNA (Qiagen, 13323) and total RNA (Qiagen, 74104) were extracted from 18485 and primary HuMECs according to the manufacturer’s recommendations (Agilent, 400800). Total RNA (0.5 µg) was converted into cDNA using the high-capacity cDNA reverse transcription kit (Roche, 4368814). Genomic DNA and cDNA were amplified using specific primers (F, TTTAGCTCATCAGCTTATTTCA; and R, GATGGCCTAAA-GACTTACCTGCT) at the miR-424/503 locus and flanking the SNP Rs757309. PCR products were analyzed by Sanger sequencing.

Patient samples and data analysis
Patient data were assessed from METABRIC and TCGA corresponding to breast cancer samples with available whole-genome DNA CNAs, mRNA expression data, and clinicopathological data. TCGA samples were profiled using Affymetrix SNP 6.0 arrays and Agilent G4502A custom microarrays, and METABRIC samples were profiled using Affymetrix SNP 6.0 arrays and Illumina HT-12 microarrays. These sets were collected from the TCGA Data Portal [https://tcga-data.nci.nih.gov/tcga] and the European Genome-Phenome Archive (EGA) database [EGA5000000000083]. The TCGA data set also included level 3 methylation profiling data obtained on the Illumina HumanMethylation450 platform and downloaded from the University of California at Santa Cruz Cancer Browser [https://genome-cancer.ucsc.edu] and RPPA data with expression levels for ~200 proteins. Array-CGH data were analyzed defining breast cancers with ("miR-DEL") versus without ("miR-non-DEL") miR-424 (322)/503 deletion. Patients’ data analysis is described in detail in the Supplemental Material.

Acknowledgments
This work was partially supported by the Agilent Technologies Leader Award (J.M.S. and C.C.-C.), the National Cancer Center (R.R.-B. and A.G.), the Irma T. Hirschl Research Award (J.M.S.), Marie Skłodowska-Curie grant number 745808 [R.R.-B.], and the J.G.W. Patterson Foundation (D.L.-N.). D.L.-N. and R.R.-B. established the animal models described. D.L.-N., R.R.-B., and E.A.N. performed the in vivo, cell, and molecular biology experiments with the assistance of T.Z.Z., A.G., and E.E. Computational analysis was performed by P.F., F.S.-G., D.B., J.Y., and F.B. Pathological analysis of mouse tumors was supervised by C.C.-C. Data analysis and interpretation were performed by D.L.-N., R.R.-B., E.N., P.F., F.B., and J.M.S. The experimental plan was conceived by J.M.S. and D.L.-N. The manuscript was written by J.M.S. with the assistance of D.L.-N. and E.N. All authors provided input and read and approved the final version of the manuscript.

References

yonowicz E, Gladoun N, de la Iglesia-Vicente J, et al. 2012. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tu-


Ebbehus SH, Scaltriti M, Bialucha CU, Morse N, Kastenhuber ER, Wen HY, Dow LE, Basela J, Lowe SW. 2016. Pten loss asso-
mates MAPK pathway dependency in HER2/neu breast carci-


Finnerty JR, Wang WX, Hebert SS, Wilfred BR, Mao G, Nelson PT.


Bcl-2 inhibits alveolar cell apoptosis during involution and ac-

Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrlik JJ, Kho-

kha R, Moorehead RA. 2007. Transgenic overexpression of


King H, Alexsíc T, Haluska P, Macaulay VM. 2014. Can we un-


Kucab JE, Dunn SE. 2003. Role of IGF-1R in mediating breast can-


Long XH, Mao JH, Peng AF, Zhou Y, Huang SH, Liu ZL. 2013. Tu-


Mason KD, Carpinelli MR, Fletcher JJ, Collinge JJ, Hilton AA, El-


miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy


*Genes Dev.* 2017, 31: Access the most recent version at doi:10.1101/gad.292318.116

---

**Supplemental Material**
http://genesdev.cshlp.org/content/suppl/2017/04/12/31.6.553.DC1

**References**
This article cites 81 articles, 16 of which can be accessed free at:
http://genesdev.cshlp.org/content/31/6/553.full.html#ref-list-1

**Creative Commons License**
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

**Email Alerting Service**
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here.

---

**Boost NGS microRNA profiling. Read about 3 methods tested**

---

© 2017 Rodriguez-Barrueco et al.; Published by Cold Spring Harbor Laboratory Press